
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics is in a unique position to address severe genetic rare diseases through its RNA-based therapeutics. With a strong pipeline of promising drugs and a focus on cholestatic diseases, the Company has a strong competitive advantage in this space. Despite facing significant competition and regulatory risks, ProQR's innovative approach to targeting RNA holds great potential for success in the future. The Company's healthy financials, including a strong cash position and strategic partnerships, also bode well for its future prospects.
Bears say
ProQR Therapeutics is a biopharmaceutical company with a single focus on RNA-based therapeutics for rare genetic diseases. While the potential for market exclusivity and orphan drug designations could provide some protection, the company faces significant competition in the gene therapy/RNA medicines space. Additionally, the need for future fundraising and the complexity and uncertainty of valuing a development stage company contribute to the negative outlook on the stock.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares